您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

中国医药研发对照标品提供商
Non-clinical Research-used
Medicine Sample Provider

当前本网站药物产品种数共 8285 处方药 7912 非处方药 267 保健品/医疗用具 106

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国际免费电话:
QQ客服1:1793093587
QQ客服2:1586083059
QQ客服3:2786706041
QQ客服6:2992753224
QQ客服7:2394834588

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 加拿大药房
产地国家: 加拿大
所属类别: 作用于呼吸系统药物->哮喘药物
处方药:处方药
包装规格: 50微克 20胶囊
计价单位:
   
生产厂家中文参考译名:
诺华
生产厂家英文名:
Novartis
该药品相关信息网址1:
http://www.novartis.com/newsroom/media-releases/en/2013/1730580.shtml
原产地英文商品名:
Ultibro Breezhaler Inhalation powder capsules 50mcg 20 caps
中文参考商品译名:
格隆溴铵吸入胶囊50微克 20胶囊
原产地国家批准上市年份:
0000/00/00
英文适应病症1:
Chronic bronchitis
英文适应病症2:
emphysema
临床试验期:
完成
中文适应病症参考翻译1:
慢性支气管炎
中文适应病症参考翻译2:
肺气肿
药品信息:
英文药名:ultibro(Glycopyrronium Bromide inhalation capsules) 中文药名:格隆溴铵吸入胶囊 生产厂家:瑞士诺华日本公司 药品介绍 适用症 缓解慢性支气管炎,肺气肿 剂量和用法 通常情况下,它被吸入与设备的辅助吸入此药每日一次只(110μg如茚达特罗和50μg的为格隆)一旦胶囊成人。 注意事项 这种药物可以用于治疗慢性阻塞性肺疾病的症状的长期管理。这种药物是不被用于急性治疗的目的在慢性阻塞性肺疾病的发作的药物。 Once-daily Ultibro® Inhalation Capsules (QVA149) for COPD Launched in Japan Dual bronchodilation with Ultibro® is expected to set a new standard of care in COPD by combining the proven efficacy benefits and safety profiles of two established Novartis COPD treatments, the LABA*, Onbrez® Inhalation Capsules (indacaterol), and the LAMA**, Seebri® Inhalation Capsules (glycopyrronium bromide). All Novartis inhaled COPD portfolio products are developed for delivery via a single-dose dry powder inhaler (SDDPI) called the Breezhaler® inhalation device which has low air flow resistance, making it suitable for patients with airflow limitation1. The Breezhaler® device allows patients to hear, feel and see that they have taken the full dose correctly. Ultibro® was approved in Japan and EU (under the brand name Ultibro® Breezhaler®) in September, and has since been launched in Germany and Netherlands. US submission is anticipated in the second half of 2014. Ultibro®, Seebri®, Onbrez® and Breezhaler® are registered trademarks of Novartis AG. * a long-acting beta2-adrenergic agonist, ** a long-acting muscarinic antagonist
更新日期: 2014-06-08
附件:
201462921513236.pdf    

 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:info.shijiebiaopin.com@gmail.com, info@shijiebiaopin.com